With the Food and Drug Administration (FDA) approving Vanda Pharmaceuticals' earlier-rejected schizophrenia drug - Fanapt (iloperidone) - a whopping eight-fold increase, a 643 percent jump, in the shares of the Rockville, Maryland-based drugmaker was nothing short of astonishing!

Shares of drug developer Human Genome Sciences Inc. plummeted to nearly half Monday as the company’s results for the developing hepatitis C drug Albuferon in a late-stage trial, failed to show numerically better efficacy compared to standard-of-care.

The Food and Drug Administration said there were concerns regarding serious side effects from three popular asthma medicines which could increase the hospitalization risk as well as death risk in some users.

CNSI has secured an order worth $32 million from Los Alamos National Laboratory (LANL) to provide lab-wide telecommunications support services.

Under the arrangement, CNSI will operate and maintain the Los Alamos Integrated Communication System (LAICS), including engineering, system upgrades, enhancements and additions.